Dexcom's revenue growth remains sluggish, leading to a decline in its share price.

• On Thursday, Dexcom's shares dropped despite the company's third-quarter results surpassing expectations, but revealing sluggish revenue growth.
• According to a release, the company's revenue grew by 2% from $975 million the previous year.
• Teri Lawver, Dexom's chief commercial officer, will retire at the end of the year.

On Thursday, shares of fell 9% in extended trading after the company's third-quarter results showed a decline in U.S. revenue year over year, despite beating analysts' expectations.

Here's how the company did:

• Earnings per share: 45 cents adjusted vs. 43 cents expected by LSEG
• Revenue:  $994 million vs. $990 million expected by LSEG

Dexcom's U.S. revenue decreased 2% from $713.6 million the previous year, while the company's net income increased by 2 cents per share to $134.6 million from $120.7 million in the same period last year.

Dexcom provides a range of products, including continuous glucose monitors (CGMs), for individuals with diabetes. In August, the company introduced its first over-the-counter product, Stelo, aimed at adults who do not require insulin.

Dexcom lowered its revenue guidance for the full fiscal year from $4.20 billion to $4.35 billion in the first quarter, but maintained its guidance for the rest of the year, expecting revenue of $4 billion to $4.05 billion.

Dexcom shares plummeted more than 40% after the release of its second-quarter results in July due to a combination of factors, including a lowered guidance and a revenue miss. The CEO, Kevin Sayer, attributed the challenges to a restructuring of the sales team, fewer new customers than expected, and lower revenue per user.

During a call with investors on Thursday, the Sayer stated that the issues had improved during the third quarter.

Dexcom's chief commercial officer, Teri Lawver, will retire at the end of the year. Lawver will remain as an adviser until early next year, and Sayer will take over as head of the commercial organization while Dexcom searches for a new chief commercial officer.